RBRajiv Kumar Bedi

Rajiv Kumar Bedi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rajiv Kumar Bedi has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structure-Based Design of Potent Pan-YTHDF Ligands

    by Francesco Errani, Francesco Nai, Elena Bochenkova, Marcin Herok, Annalisa Invernizzi, Rajiv Kumar Bedi, Yaozong Li, FrantišeK ZálEšák, Amedeo Caflisch

    The reader proteins YTHDF1-3 recognize m6A-RNA in the cytosol. Here, we present a structure-based medicinal chemistry campaign that culminated in the pan-YTHDF inhibitor 34 (Kd = 0.14 μM for YTHDF2 by calorimetry), which is selective against YTHDC1 and YTHDC2. The high-resolution crystal structures of the complex of YTHDF2 with six members of the series validate the structure-based design. Using the structural information, we designed compound 31 (IC50 = 0.22 μM for YTHDF2) and a negative control, i.e., its methylated analogue 31b. The cellular thermal shift assay provides evidence of YTHDF2 target engagement in cells for inhibitors 34 and 31, while the negative control 31b is inactive. Compounds 34 and 31 inhibit the proliferation of the AML cell lines MOLM-13 and THP-1. The inhibition of the YTHDF readers by 31 increases the level and stability of the transcript of TNFRSF1B. This renders THP-1 cells more sensitive to TNF-α-induced toxicity.

  • Recognition Loop Dynamics Differentiates m6A-mRNA Reader Domains of YTHDF Proteins

    by Yaozong Li, Rajiv Kumar Bedi, Pedro Ojeda-May, Amedeo Caflisch

    The three human YTH-domain family proteins (YTHDF1, YTHDF2, and YTHDF3) are highly homologous and recognize the N6-methyladenosine (m6A) modification of mRNA with essentially identical binding modes and affinities. This homogeneity challenges the well-established view that different YTHDF proteins play distinct cellular functions (the specificity view), with an emerging argument that these proteins may instead play redundant roles. To study this apparent discrepancy, we investigated the mechanism of binding of m6A-containing RNA using mutagenesis, X-ray crystallography, isothermal titration calorimetry (ITC), and molecular dynamics simulations. Specifically, we compared different properties of YTHDF proteins, including their binding capacities to m6A-RNA, conformational changes, and homodimerization propensity. Our results show that the YTHDF proteins share an identical binding mode of m6A-RNA, which requires rare protonation of m6A for binding. Additionally, the three proteins share a similar open-closed switch for their recognition loop regulating the m6A binding. On the other hand, ITC data and crystal structures provide consistent evidence that the YTHDF proteins differ significantly in the flexibility of the recognition loop and its conformational preferences. Only YTHDF1 can homodimerize, which prevents binding to m6A-RNA. Furthermore, we integrate the available biophysical and biochemical evidence to define both the shared and distinct features of YTHDF1–3 in m6A-RNA recognition and propose a hybrid model that reconciles the redundancy-specificity debate. Finally, we discuss the limitations of the work and propose experiments for validating the presented model.

  • Open Access

    Ligand-Induced Opening of a Cryptic Pocket in METTL14

    by Ivan Corbeski, Rajiv Kumar Bedi, Christian M. Matter, Fiona Stamm, Elena Bochenkova, Marcin Herok, Michael J. Hartshorn, Amedeo Caflisch

    The complex of methyltransferase-like proteins 3 and 14 (METTL3–14) is the main human enzyme that deposits the most abundant internal mRNA modification, N6-methyladenosine (m6A). In the heterodimeric complex, METTL3 acts as a catalytic subunit while METTL14 is involved in mRNA binding and complex stabilization. Here, we present the discovery of small-molecule ligands that bind to a cryptic pocket in METTL14 by protein crystallography. A comparative analysis of crystal structures revealed that the METTL14 cryptic pocket is closed in the apo structure of METTL3–14, and in the structures of METTL3–14 in the complex with the cosubstrate S-adenosyl-methionine (SAM) and a large number of SAM-competitive inhibitors. We first discovered compounds 1 and 2 that bind to both the SAM pocket in METTL3 and the cryptic pocket in METTL14. With this structural information, we designed compound 3 that binds only to the METTL14 cryptic pocket. Compound 3 does not inhibit the catalytic activity of METTL3–14 but can be used as an anchor for heterobifunctional molecules. We propose a route for its further development into heterobifunctional ligands, e.g., proteolysis targeting chimeras (PROTACs).


  • Open Access

    Discovery of YTHDF2 Ligands by Fragment-Based Design

    by Annalisa Invernizzi, Francesco Nai, Rajiv Kumar Bedi, Pablo Andrés Vargas-Rosales, Yaozong Li, Elena Bochenkova, Marcin Herok, František Zálešák, Amedeo Caflisch

    N 6-Adenosine methylation is the most abundant modification of mRNA. The three members of the YTH domain family proteins (YTHDF1–3) recognize in the cytoplasm the m6A-RNA modification. We screened a library of about 500,000 fragments (i.e., molecules with 11–20 non-hydrogen atoms) by docking into YTHDF2, which resulted in the identification of six active compounds among 47 tested in vitro (hit rate of 13%). The acquisition of 28 analogues of the docking hits provided an additional set of 10 active compounds (IC50 < 100 μM). Protein crystallography-guided optimization of a ligand-efficient fragment by the synthesis of 32 derivatives culminated in a series of YTHDF2 ligands, which show low-micromolar affinity measured by a fluorescence polarization (FP) assay and a homogeneous time-resolved fluorescence-based (HTRF) assay. The series is characterized by very favorable ligand efficiency (of about 0.3–0.4 kcal/mol per non-hydrogen atom). Compound 23 binds to YTHDF2 according to the FP and HTRF assays with a K d value of 1.3 μM and an IC50 value of 11 μM, respectively, and it is selective against all of the other YTH reader proteins. Several compounds of the series bind to the three YTHDF proteins with similar low-micromolar affinity, while they are less potent for YTHDC1 and YTHDC2. In contrast, compounds 17 and 30 bind also to YTHDC2, with K d of 6.3 and 4.9 μM, respectively. We also disclose six crystal structures of YTHDF2 in the complex with the fragments identified by docking.


  • Open Access

    Discovery of YTHDF2 ligands by fragment-based design

    by Annalisa Invernizzi, Francesco Nai, Rajiv Kumar Bedi, Pablo Andrés Vargas-Rosales, Yaozong Li, Elena Bochenkova, Marcin Herok, František Zálešák, Amedeo Caflisch

    N6-Adenosine methylation is the most abundant modification of mRNA. The three members of the YTH domain family proteins (YTHDF1-3) recognize in the cytoplasm the m6A-RNA modification. We screened a library of about 500,000 fragments (i.e., molecules with 11 to 20 non-hydrogen atoms) by docking into YTHDF2, which resulted in the identification of six active compounds among 47 tested in vitro (hit rate of 13%). The acquisition of 28 analogues of the docking hits provided an additional set of 10 active compounds (IC50 < 100 µM). Protein crystallography-guided optimization of a ligandefficient fragment by the synthesis of 32 derivatives culminated in a series of YTHDF2 ligands which show low-micromolar affinity measured by a fluorescence-polarization (FP) assay and a homogeneous time-resolved fluorescence-based (HTRF) assay. The series is characterized by very favorable ligand efficiency (of about 0.3 – 0.4 kcal/mol per non-hydrogen atom). Compound 23 binds to YTHDF2 according to the FP and HTRF assays with a Kd value of 1.3 µM and IC50 value of 11 µM, respectively, and it is selective against all the other YTH reader proteins. Several compounds of the series bind to the three YTHDF proteins with similar low-micromolar affinity, while they are less potent for YTHDC1 and YTHDC2. In contrast, compounds 17 and 30 bind also to YTHDC2, with Kd of 6.3 µM and 4.9 µM, respectively. We also disclose six crystal structures of YTHDF2 in the complex with the fragments identified by docking.

  • Open Access

    Selective CBP/EP300 Bromodomain Inhibitors: Novel Epigenetic Tools to Counter TNF-α-Driven Inflammation

    by Katherine A. Gosselé, Irene Latino, Eleen Laul, Mariia S. Kirillova, Vlad Pascanu, Emanuele Carloni, Rajiv K. Bedi, Chiara Pizzichetti, Amedeo Caflisch, Santiago F. González, et al.

    Tumor necrosis factor α (TNF-α) is a central driver of inflammation in autoimmune conditions such as Crohn’s disease and rheumatoid arthritis (RA). Targeting epigenetic regulators involved in cytokine expression holds therapeutic promise, yet the precise role of the CBP/EP300 bromodomains (BRDs) in modulating immune responses remains poorly understood. Here, we introduce a distinct class of selective CBP/EP300-BRD inhibitors based on a unique 3-methylcinnoline acetyl-lysine mimic, identified through high-throughput fragment docking. These inhibitors significantly reduce TNF-α-driven cytokine expression in vitro by blocking NFκB signaling in immune cells. In vivo, BRD inhibition led to a robust anti-inflammatory effect, decreasing cytokine secretion (including IL-1β, MCP-1, IL-1α, and IL-6) and preventing immune cell migration to inflamed lymph nodes in a TNF-α-stimulated murine model. Our findings highlight CBP/EP300-BRDs as promising targets for autoimmune therapy, with these non-cytotoxic inhibitors offering a potential complementary approach for RA and other TNF-α-mediated inflammatory conditions.


  • Open Access

    Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity

    by Iván Cheng-Sánchez, Katherine Gosselé, Leonardo Palaferri, Eleen Laul, Gionata Riccabella, Rajiv K. Bedi, Yaozong Li, Anna Müller, Ivan Corbeski, Amedeo Caflisch, et al.

    We present the development of dCE-2, a structurally novel PROTAC targeting the CREB-binding protein (CBP) and E1A-associated protein (EP300)-two homologous multidomain enzymes crucial for enhancer-mediated transcription. The design of dCE-2 was based on the crystal structure of an in-house bromodomain (BRD) inhibitor featuring a 3-methyl-cinnoline acetyl-lysine mimic acetyl-lysine mimic discovered by high-throughput fragment docking. Our study shows that, despite its modest binding affinity to CBP/EP300-BRD, dCE-2's remarkable protein degradation activity stems from its good cooperativity, which we demonstrate by the characterization of its ternary complex formation both in vitro and in cellulo. Molecular dynamics simulations indicate that in aqueous solvents, this active degrader populates both folded and extended conformations, which are likely to promote cell permeability and ternary complex formation, respectively.


  • Open Access

    Structure-Based Design of a Potent and Selective YTHDC1 Ligand

    by František Zálešák, Francesco Nai, Marcin Herok, Elena Bochenkova, Rajiv K. Bedi, Yaozong Li, Francesco Errani, Amedeo Caflisch

    N6-Adenosine methylation (m6A) is a prevalent post-transcriptional modification of mRNA, with YTHDC1 being the reader protein responsible for recognizing this modification in the cell nucleus. Here, we present a protein structure-based medicinal chemistry campaign that resulted in the YTHDC1 inhibitor 40, which shows an equilibrium dissociation constant (Kd) of 49 nM. The crystal structure of the complex (1.6 Å resolution) validated the design. Compound 40 is selective against the cytoplasmic m6A-RNA readers YTHDF1-3 and YTHDC2 and shows antiproliferative activity against the acute myeloid leukemia (AML) cell lines THP-1, MOLM-13, and NOMO-1. For the series of compounds that culminated into ligand 40, the good correlation between the affinity in the biochemical assay and antiproliferative activity in the THP-1 cell line provides evidence of YTHDC1 target engagement in the cell. The binding to YTHDC1 in the cell is further supported by the cellular thermal shift assay. Thus, ligand 40 is a tool compound for studying the role of YTHDC1 in AML.


  • Open Access

    Structure-based Design of CBP/EP300 Degraders: When Coopera-tivity Overcomes Affinity

    by Ivan Cheng-Sanchez, Katherine Gosselé, Leonardo Palaferri, Eleen Laul, Gionata Riccabella, Rajiv Bedi, Yaozong Li, Anna Müller, Amedeo Caflisch, Cristina Nevado

    Here we present the development of dCE-2, a structurally novel PROTAC targeting the CREB-binding protein (CBP) and E1A-associated protein (EP300) – two homologous multidomain enzymes crucial for enhancer-mediated transcription. The design of dCE-2 was based on the crystal structure of an in-house bromodomain (BRD) inhibitor featuring as acetyl-lysine mimic a 3-methyl cinnoline discovered by high-throughput fragment docking. Our study shows that, despite its modest binding affinity to CBP/EP300-BRD, dCE-2 remarkable protein degradation activity stems from its excellent cooperativity, which we demonstrate by the characterisation of its ternary complex formation both in vitro and in cellulo. Molecular dynamics simulations indicate that in aqueous solvent this active degrader populates both folded and extended conformations which are likely to promote cell permeabil-ity and ternary complex formation, respectively.

  • Open Access

    Development of a novel class of CBP/EP300 bromodomain inhibitors which block TNF-α induced NFκB signaling

    by Katherine Gosselé, Irene Latino, Eleen Laul, Mariia Kirillova, Vlad Pascanu, Emanuele Carloni, Rajiv Bedi, Amedeo Caflisch, Santiago Gonzalez, Cristina Nevado

    Tumor Necrosis Factor α (TNF-α) is an inflammatory cytokine that is a key mediator in autoimmune disorders such as Crohn’s disease and rheumatoid arthritis (RA). Targeting epigenetic regulators of cytokine transcription and signaling is a promising therapeutic approach. However, the specific mechanisms by which they contribute to the immune response are not well established yet. Here, we present a new class of selective CBP/EP300-bromodomain (BRD) inhibitors comprising a 3-methylcinnoline as acetyl-lysine mimic discovered by high-throughput docking of a fragment library. These compounds inhibit NFκB signaling in THP-1 cells, reducing TNF-α-induced cytokine expression in vitro. Furthermore, when tested in vivo, BRD inhibitors reduced the pro-inflammatory response by decreasing the secretion of IL-1β, MCP-1, IL-1α, and IL-6 from TNF-α-stimulated animals and inhibiting the migration of innate immune cells towards the draining lymph node. The results of this study confirmed CBP/EP300-BRD as valid therapeutic targets for autoimmune diseases and our inhibitors represent a promising new class of non-cytotoxic therapeutic agents for treating RA.